Search

Displaying results 511 - 520 of 4539 in total
  1. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338] … [A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain.

    Products: LACDIGEST 2250 U CIGNEME TABLETI, 100 TABLET, LACDIGEST 2250 U CIGNEME TABLETI, 50 TABLET
  2. Drug

    Cefditoren

    go.drugbank.com/drugs/DB01066
    Approved

    It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.

  3. Drug

    Threonine

    go.drugbank.com/drugs/DB00156
    ApprovedInvestigationalNutraceutical

    An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.

    Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI)
  4. Drug

    Cefdinir

    go.drugbank.com/drugs/DB00535
    ApprovedInvestigational

    Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.

  5. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [L39779] Health Canada also approved the use of abrocitinib in pediatric patients 12 years and older.[L42395] … Atopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells.

  6. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970] … Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23.

  7. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.

  8. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable. … [A237520] Originally developed by Baxter International Inc., TICOVAC was subsequently acquired by Pfizer Inc. in 2014.[L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050]

  9. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    [A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937] … [A252937] Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET.

  10. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase … [L64050,L64051] The approval covers adults and pediatric patients 8 years of age and older and was based on a statistically significant reduction in daily cornstarch intake, a surrogate endpoint, with